GNS Healthcare (GNS), a Cambridge, MA-based precision medicine company, raised an additional $6m in equity funding.
The round was led by Amgen Ventures with participation from existing investor Alexandria Real Estate Equities.
The funds will be used to further develop the company’s REFS™ causal machine learning and simulation platform and solutions across drug discovery & development, value-based drug solutions, care management, and health system business optimization. With this investment, Amgen Ventures joined other biopharma companies Celgene and Zambon Pharmaceuticals, health plans Regence Blue Cross Blue Shield (Cambia Health Solutions), and Horizon Blue Cross of NJ and provider Heritage Provider Network, in addition to Mitsui, GHO Capital, and Fort Rock Capital as shareholders of GNS.
Led by Colin Hill, Chairman and CEO and Co-Founder, GNS Healthcare provides REFS™ (Reverse Engineering & Forward Simulation), a patented causal machine learning platform which analyzes data sets beyond correlation, instead inferring causal mechanisms between variables to answer questions such as: How will the patient respond to this treatment? What if we choose one intervention over another?
REFS™ uses a two-step process, first reverse engineering causative mechanisms from multi-model datasets, then running “what if?” simulations to determine which treatments and therapeutics will produce the best outcomes for every individual in the population.
Health plans, bio-pharmaceutical companies, healthcare providers, foundations, academic medical centers, and self-insured employers use GNS’ cloud-based solutions to solve problems including those surrounding metabolic syndrome, medication adherence, end-of-life care, preterm birth, personalized care pathways in specialty care, oncology, and diabetes, new drug target discovery, patient stratification in clinical trials, etc.